CSL makes $4bn+ move in mRNA vaccines with Arcturus deal
pharmaphorum
NOVEMBER 2, 2022
CSL’s vaccines unit CSL Seqirus division is paying Arcturus $200 million upfront to gain access to its self-amplifying mRNA technology platform and exclusive licenses to several vaccine candidates, with another $4.3 billion on offer in milestones if the programmes meet development and commercial objectives.
52 
Let's personalize your content